$6.44 2.7%
ADPT Stock Price vs. AI Score
Data gathered: December 9

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Adaptive Biotechnologies (ADPT)

Analysis generated August 15, 2024. Powered by Chat GPT.

Adaptive Biotechnologies is a clinical-stage biotechnology company that leverages the infrastructure of the adaptive immune system to develop diagnostic tests and drug discovery applications. The company uses a combination of state-of-the-art technology and advanced artificial intelligence to provide deeper insights into immune system architecture and function, applying these insights to commercial diagnostics and therapeutic products.

Read full AI stock Analysis

Stock Alerts - Adaptive Biotechnologies (ADPT)

company logo Adaptive Biotechnologies | December 9
Price is up by 6.2% in the last 24h.
company logo Adaptive Biotechnologies | December 3
Price is down by -5.4% in the last 24h.
company logo Adaptive Biotechnologies | December 2
Price is up by 5.1% in the last 24h.
company logo Adaptive Biotechnologies | November 30
Employee Rating is down by 3.2% over the last month.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.


Adaptive Biotechnologies
Price $6.44
Target Price Sign up
Volume 1,100,000
Market Cap $925M
Year Range $2.34 - $6.53
Dividend Yield 0%
Analyst Rating 71% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2446M59M-13M-32M-28M0.000
Q2 '2443M70M-27M-46M-42M-0.310
Q1 '2439M66M-27M-48M-44M-0.330
Q4 '2343M88M-45M-69M-71M-0.300
Q3 '2334M60M-26M-50M-51M-0.350

Insider Transactions View All

PISKEL KYLE filed to sell 154,330 shares at $5.
November 19 '24
Taylor Stacy L filed to sell 139,365 shares at $4.5.
August 23 '24
BOBULSKY SUSAN filed to sell 255,265 shares at $3.4.
March 6 '24
BOBULSKY SUSAN filed to sell 248,290 shares at $3.4.
March 6 '24
ROBINS CHAD M filed to sell 2,619,495 shares at $3.4.
March 6 '24

What is the Market Cap of Adaptive Biotechnologies?

The Market Cap of Adaptive Biotechnologies is $925M.

What is the current stock price of Adaptive Biotechnologies?

Currently, the price of one share of Adaptive Biotechnologies stock is $6.44.

How can I analyze the ADPT stock price chart for investment decisions?

The ADPT stock price chart above provides a comprehensive visual representation of Adaptive Biotechnologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adaptive Biotechnologies shares. Our platform offers an up-to-date ADPT stock price chart, along with technical data analysis and alternative data insights.

Does ADPT offer dividends to its shareholders?

As of our latest update, Adaptive Biotechnologies (ADPT) does not offer dividends to its shareholders. Investors interested in Adaptive Biotechnologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Adaptive Biotechnologies?

Some of the similar stocks of Adaptive Biotechnologies are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.